900 results match your criteria Expert Review of Hematology [Journal]


Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia.

Expert Rev Hematol 2019 Apr 16. Epub 2019 Apr 16.

a Department of Hematology , Juntendo University Graduate School of Medicine , Tokyo , Japan .

Introduction: Acute megakaryoblastic leukemia (AMegL) is a rare hematological neoplasm most often diagnosed in children and is commonly associated with Down syndrome (DS). Although AMegLs are specifically characterized and typically diagnosed by megakaryoblastic expansion, recent advancements in molecular analysis have highlighted the heterogeneity of this disease, with specific cytogenic and genetic alterations characterizing different disease sub-types. Areas covered: This review will focus on describing recurrent molecular variations in both DS and non-DS pediatric AMegL, their role in promoting leukemogenesis, their association with different clinical aspects and prognosis, and finally, their influence on future treatment strategies with a number of specific drugs beyond conventional chemotherapy already under development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1609351DOI Listing

Getting personal with myelodysplastic syndromes: is now the right time?

Expert Rev Hematol 2019 Apr 12:1-10. Epub 2019 Apr 12.

a Section of Hematology, Department of Internal Medicine , Yale University School of Medicine , New Haven , CT , USA.

Introduction: Commonly used scoring systems rely on blood counts, histological and cytological examination of bone marrow and peripheral blood as well as cytogenetic assessments to estimate prognosis of patients with myelodysplastic syndromes (MDS) and guide therapy decisions. Next-generation sequencing (NGS) has identified recurrent genetic abnormalities in up to 90% of patients with MDS and may provide important information regarding the pathogenesis of the disease, diagnostic and prognostic evaluation, and therapy selection. Areas covered: Herein, the authors review the role of NGS in diagnosis, treatment, and prognosis of MDS at various disease stages, and discuss advantages and caveats of incorporating molecular genetics in routine management of MDS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1592673DOI Listing
April 2019
2 Reads

Updates on thrombotic events associated with multiple myeloma.

Expert Rev Hematol 2019 Apr 8:1-11. Epub 2019 Apr 8.

a Department of Clinical Therapeutics, School of Medicine , National and Kapodistrian University of Athens , Athens , Greece.

Introduction: Despite the implementation of thromboprophylaxis guidelines, the risk of venous thromboembolism (VTE) in patients with Multiple Myeloma (MM) remains significant. There is, therefore, a need for more sensitive risk stratification tools and optimization of our thromboprophylaxis approach. Areas covered: Since 2015 there have been no breakthrough data in this field. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1604214DOI Listing
April 2019
1 Read

A systematic literature review of incidence, mortality and relapse of patients diagnosed with chronic graft versus host disease.

Expert Rev Hematol 2019 Apr 6. Epub 2019 Apr 6.

f Department of Oncology-Pathology , Karolinska Institute , Sweden.

Introduction: Chronic graft-versus-host disease (chronic GVHD) is a leading cause of late death and contributes significantly to morbidity following hematopoietic stem cell transplantation. This study aims to provide a systematic literature review on incidence, mortality and relapse of chronic GVHD patients. Areas covered: The authors searched for English-language articles published between 2007 and 2017 using PubMed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1605288DOI Listing
April 2019
1 Read

An update on the 'danger theory' in inhibitor development in haemophilia A.

Expert Rev Hematol 2019 Apr 5. Epub 2019 Apr 5.

a Van Creveldkliniek, University Medical Center Utrecht, Utrecht University , Utrecht , The Netherlands.

Introduction: Nowadays, one of the most serious treatment complications in haemophilia A is the formation of neutralizing antibodies against coagulation factor VIII (FVIII). These so-called inhibitors develop in about 30% of all patients with severe haemophilia A. Once formed, inhibitors reduce FVIII efficacy in blood coagulation, which has a negative impact on patients' health and quality of life and significantly increases haemophilia A treatment costs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1604213DOI Listing
April 2019
1 Read

Risks and patient outcomes of surgical intervention for hemophilic arthropathy.

Expert Rev Hematol 2019 Mar 30:1-9. Epub 2019 Mar 30.

a Department of Orthopedic Surgery , La Paz University Hospital , Madrid , Spain.

Introduction: Surgical interventions usually needed for hemophilic arthropathy include arthroscopic synovectomy, alignment osteotomy, arthroscopic joint debridement, radial head removal, arthrodesis of the ankle, and total joint arthroplasty (elbow, hip, knee, ankle). Areas covered: Whatever the surgical technique, appropriate surgical hemostasis must be achieved through infusion of concentrate of the deficient factor (factor VIII or factor IX), either in recombinant or plasma-derived form, at the correct dosage (ideally for 10-14 days). In patients with inhibitors, there are also the aPCCs (activated prothrombin complex concentrates) and rFVIIa (recombinant activated FVII). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1602035DOI Listing
March 2019
2 Reads

Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status.

Expert Rev Hematol 2019 Mar 29:1-15. Epub 2019 Mar 29.

e Department of Oncology and Pathology , Karolinska Institutet , Stockholm , Sweden.

Introduction: Chronic graft-versus-host disease (GVHD) is a serious complication of allogeneic hematopoietic stem cell transplantation (HSCT). This study aims to provide a systematic overview of evidence on the health-related quality of life (HRQoL) and functional capacity of HSCT patients with National Institutes of Health (NIH)-defined chronic GVHD. Areas covered: English-language articles published between 2007 and 2017 were searched using PubMed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1602036DOI Listing
March 2019
1 Read

Contemporary management of essential thrombocythemia in children.

Expert Rev Hematol 2019 Mar 29. Epub 2019 Mar 29.

b Department of Women's and Children's Health, Pediatric Hemato-Oncology , University of Padova , Padova , Italy.

Introduction: Essential thrombocythemia (ET) is a disease which is extremely rare in children. Only recently, data on pediatric ET have become available Areas covered: In children with sustained platelet count over 450 x 10/L, secondary thrombocytosis must be ruled out. ET workup comprehends research of JAK2V617F, CALR and MPL mutations and bone marrow biopsy (BM). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1602034DOI Listing
March 2019
18 Reads

Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.

Expert Rev Hematol 2019 Mar 28:1-8. Epub 2019 Mar 28.

d Division of Pediatric Hematology and Oncology , China Medical University Children's Hospital , Taichung , Taiwan.

Objectives: Three iron chelators are used to treat transfusion-dependent beta-thalassemia: desferrioxamine (DFO), deferasirox (DFX), and deferiprone (DFP). Compliance is low for DFO as it cannot be administered orally. Combined administration of DFP and DFX is orally available, however, the therapeutic mechanism is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1593823DOI Listing
March 2019
4 Reads

Ibrutinib for the treatment of chronic lymphocytic leukemia.

Expert Rev Hematol 2019 Mar 27:1-12. Epub 2019 Mar 27.

a Department of Hematology , Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda , Milano , Italy.

Introduction: Chemoimmunotherapy has improved outcomes in chronic lymphocytic leukemia, yet it is not curative, with very high relapse rates, and is associated with a significant risk of toxicities. Moreover, patients with higher-risk genetic abnormalities continue to experience poorer outcomes and lower survival. Recently, novel targeted therapies have been developed to increase efficacy and reduce toxicity. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1597703DOI Listing
March 2019
4 Reads

Timing treatment for smoldering myeloma: is earlier better?

Expert Rev Hematol 2019 Mar 25:1-10. Epub 2019 Mar 25.

b School of Medicine , Complutense University , Madrid , Spain.

Introduction: In 2014, the International Myeloma Working Group determined that patients with ultra-high-risk smoldering multiple myeloma (SMM) should be considered for treatment as per patients with symptomatic multiple myeloma (MM), despite not having CRAB (hyperCalcemia, Renal insufficiency, Anemia, Bone disease) symptoms. Current research is elucidating whether patients with high-risk, and even intermediate-risk, SMM could benefit from early therapeutic strategies aimed at delaying progression to active MM and prolonging survival. Areas covered: The authors conducted a systematic literature search using PubMed to identify a series of patients with SMM in which prognostic and predictive factors for progression were investigated, plus the main clinical trials in SMM. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1599281DOI Listing
March 2019
6 Reads

An update on biology, diagnosis and treatment of primary plasma cell leukemia.

Expert Rev Hematol 2019 Mar 23:1-9. Epub 2019 Mar 23.

c Scientific Direction, Laboratory of Clinical Research and Advanced Diagnostics , IRCCS-CROB, Referral Cancer Center of Basilicata , Rionero in Vulture (Pz) , Italy.

Introduction: Primary plasma cell leukemia (PPCL) is one of the most aggressive hematological malignancies. The prognosis of PPCL patients remains poor, although some improvements have been made in recent years. Areas covered: In this review recent clinical and biological advances in PPCL are reported. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1598258DOI Listing
March 2019
7 Reads

Novel agents may positively impact chemotherapy and transplantation in subsets of Diffuse Large B-cell Lymphoma.

Expert Rev Hematol 2019 Mar 18. Epub 2019 Mar 18.

d Case Western Reserve University , Case Comprehensive Cancer Center , Cleveland , OH , USA .

Introduction: Molecular and biologic heterogeneity in diffuse large B-cell lymphoma (DLBCL) has resulted in a broad range of clinical outcomes. While standard frontline chemoimmunotherapy cures majority of patients with DLBCL, treatment failure in certain DLBCL subsets remains high. Prognosis in these patients is dismal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1596793DOI Listing
March 2019
1 Read

What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia.

Expert Rev Hematol 2019 Mar 18:1-3. Epub 2019 Mar 18.

d Department of Cancer Immunology , Osaka University Graduate School of Medicine , Suita City, Osaka , Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1593824DOI Listing
March 2019
1 Read

Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma.

Expert Rev Hematol 2019 Mar 15:1-10. Epub 2019 Mar 15.

d Case Comprehensive Cancer Center , Case Western Reserve University , Cleveland , OH , USA.

Introduction: Majority of patients with Hodgkin lymphoma (HL) can be successfully cured with frontline conventional therapeutics. Approximately 50-60% of those whose disease recur or is refractory to conventional treatment, can be cured with salvage therapies followed by autologous hematopoietic cell transplantation (AHCT). Conventional treatments, however, may cause significant long-term toxicities. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1593135DOI Listing
March 2019
4 Reads

An update on arginine in sickle cell disease.

Expert Rev Hematol 2019 Mar 11:1-10. Epub 2019 Mar 11.

a Hematology and Transfusion Medicine Center , University of Campinas , Campinas , Brazil.

Introduction: Recent knowledge on the pathophysiology of sickle cell disease (SCD) have emphasized the role of hemolysis and nitric oxide (NO) depletion on the occurrence of acute and chronic complications. This new paradigm raises the possibility of innovative therapeutic approaches, including arginine supplementation. Areas covered: This review comments on the role of NO in the regulation of vascular tone, as well as its impaired metabolism in hemolytic diseases. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1591948DOI Listing
March 2019
10 Reads

Can increased immunogenicity in chronic myeloid leukemia improve outcomes?

Expert Rev Hematol 2019 Mar 11:1-9. Epub 2019 Mar 11.

b Division of Malignant Hematology , Moffitt Cancer Center , Tampa , FL , USA.

Introduction: Chronic myeloid leukemia (CML) has long been thought to be the model disease for immunotherapy with its characteristic BCR-ABL fusion protein. Although targeted therapy using tyrosine kinase inhibitors (TKIs) is highly effective at inducing remission, most patients require life-long TKI to decrease the risk of relapse. In recent years, much effort has been devoted to finding ways to eliminate CML stem cells (LSCs); the source of disease persistence. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1588105DOI Listing
March 2019
4 Reads

When to use stem cell transplant in mantle cell lymphoma.

Expert Rev Hematol 2019 Mar 7:1-4. Epub 2019 Mar 7.

b Department of Hematology and Medical Oncology , Emory University Winship Cancer Institute , Atlanta , GA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1588106DOI Listing
March 2019
1 Read

Developments in diagnosis and treatment of essential thrombocythemia.

Expert Rev Hematol 2019 Mar 13;12(3):159-171. Epub 2019 Mar 13.

a Ospedale di Circolo , ASST Sette Laghi, Hematology , Varese , Italy.

Introduction: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by thrombocytosis, increased risk of thrombotic/hemorrhagic events and clonal evolution into blast phase or myelofibrosis. Areas covered: The authors will discuss biology, diagnosis, prognosis, therapy, and outcome of ET. An accurate molecular-morphologic assessment is necessary in order to properly establish diagnosis and prognosis of ET. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1585239DOI Listing
March 2019
1 Read

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.

Expert Rev Hematol 2019 Mar 18;12(3):195-205. Epub 2019 Mar 18.

a Division of Medical Oncology, Department of Internal Medicine , University of Washington School of Medicine , Seattle , WA , USA.

Introduction: Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated remarkable anti-tumor activity in B-cell malignancies and is under investigation in other hematologic malignancies and solid tumors. While highly efficacious, post-infusion T cell activity often results in massive cytokine release precipitating cytokine release syndrome (CRS), the signature toxicity of CAR T cells. This toxicity is characterized by systemic immune activation resulting in fever, hypotension, respiratory insufficiency and capillary leak. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1585238DOI Listing
March 2019
5 Reads

New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.

Expert Rev Hematol 2019 Mar 27;12(3):137-146. Epub 2019 Feb 27.

a Center for Lymphoid Malignancies, Division of Hematology and Oncology, Department of Medicine , Columbia University Medical Center, College of Physicians and Surgeons , New York , NY , USA.

Introduction: The peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group of non-Hodgkin lymphomas originating from mature T- and NK-cells. They are aggressive diseases often resistant to chemotherapy. Areas Covered: The methodology of this review involves a literature search of data published on PubMed, abstracts from international conferences, and our own research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583102DOI Listing
March 2019
8 Reads

BRAF in the cross-hairs.

Expert Rev Hematol 2019 Mar 26;12(3):183-193. Epub 2019 Feb 26.

a Leukemia Service , Memorial Sloan Kettering Cancer Center , New York , NY , USA.

Introduction: Hairy cell leukemia (HCL) is a rare, chronic B-cell lymphoproliferative disorder characterized by distinctive morphologic features and an indolent clinical course. The discovery of a recurrent activating mutation in BRAF (BRAF V600E) as a disease-defining genetic event in HCL has substantial diagnostic and therapeutic implications. Areas covered: Herein the authors review the role of BRAF V600E and RAF-MEK-ERK signaling in the pathogenesis of HCL, anecdotal clinical reports of BRAF inhibitor monotherapy in management of relapsed or refractory HCL, larger phase 2 trials investigating efficacy of BRAF inhibitor therapy for HCL, adverse effects commonly associated with BRAF inhibitor therapy, including cutaneous toxicity, and mechanisms of therapeutic resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583553DOI Listing
March 2019
2 Reads

Thrombophilia, risk factors and prevention.

Expert Rev Hematol 2019 Mar 26;12(3):147-158. Epub 2019 Feb 26.

a Haemorrhagic and Thrombotic Diseases Unit, Department of Medicine (DIMED) , Padova University Hospital , Padova , Italy.

Introduction: Fifty-three years after the first description of an inherited prothrombotic condition (antithrombin deficiency), our knowledge on hereditary and acquired causes of hypercoagulability that can predispose carriers to venous thromboembolism (VTE) has greatly improved. Areas covered: Main causes of hereditary thrombophilia are summarized alongside new prothrombotic mutations recently discovered. The main causes of acquired thrombophilia, and namely, antiphospholipid antibody syndrome and hyperhomocysteinemia, are also discussed together with other common acquired prothrombotic states characterized by an increase of procoagulant factors and/or a decrease of natural anticoagulants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583555DOI Listing
March 2019
1 Read

Overcoming challenges of venous thromboembolism in sickle cell disease treatment.

Expert Rev Hematol 2019 Mar 8;12(3):173-182. Epub 2019 Mar 8.

a Department of Hematology , Johns Hopkins School of Medicine , Baltimore , MD , USA.

Introduction: Venous thromboembolism (VTE) is a common comorbid condition found in sickle cell disease (SCD) and is associated with increased mortality for adults with SCD. The pathophysiology that leads to the thrombophilic state in SCD has been previously reviewed; however, evidence-based guidelines to aid in diagnosis, prevention, and management of VTE are lacking. Areas covered: This review article will cover the pathophysiology underlying the hypercoagulable state, the epidemiology of VTE, and management strategies of VTE in SCD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583554DOI Listing
March 2019
1 Read

Risk adapted post-transplant maintenance in multiple myeloma.

Expert Rev Hematol 2019 Feb;12(2):107-118

a Division of Hematology , Mayo Clinic , Rochester , MN , USA.

Introduction: The survival of multiple myeloma patients is increasing due to new medications, the widespread implementation of autologous stem cell transplantation and better supportive treatments. The controversy surrounding post-transplant treatment is debated due to a lack of large randomized trials comparing the different treatment modalities. The questions for each proposed treatment are whether it improves outcomes, has low cumulative toxicities and is easy to administer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1576521DOI Listing
February 2019
2 Reads

A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.

Expert Rev Hematol 2019 Feb 19;12(2):129-136. Epub 2019 Feb 19.

b International Market Access , Pharmacosmos A/S , Holbæk , Denmark.

Objectives: The efficacy of oral iron in treating iron deficiency anemia (IDA) can be limited by poor gastrointestinal (GI) absorption and adverse GI symptoms; intravenous (IV) iron is a well-established alternative. The present study compared the efficacy of two IV iron formulations in patients with IDA: iron isomaltoside (IIM) and ferric carboxymaltose (FCM).

Methods: A systematic literature review (SLR) was conducted to identify randomized controlled trials (RCTs) of IIM and FCM in patients with IDA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1575202DOI Listing
February 2019

Thrombotic complications in adult patients with severe single coagulation factor or platelet defects - an overview.

Expert Rev Hematol 2019 Feb 28;12(2):119-128. Epub 2019 Jan 28.

a Section for Hematology, Department of Clinical Science , University of Bergen , Bergen , Norway.

Introduction: Even though thrombotic events are rare in patients with coagulation deficiencies, several cases of both arterial and venous thromboses have been reported in patients with single coagulation factor defects and platelet defects. Thromboses have been described both in hemophilia A and B, von Willebrand disease as well as in many other rare congenital coagulation factor and platelet defects. Thromboses may also occur in patients with acquired hemophilia and in patients with severe thrombocytopenia due to hematological malignancies or intensive chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1570126DOI Listing
February 2019
5 Reads

Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment.

Expert Rev Hematol 2019 Feb 6;12(2):89-98. Epub 2019 Feb 6.

a Division of Hematology, Oncology Institute of Southern Switzerland and Laboratory of Experimental Hematology , Institute of Oncology Research , Bellinzona , Switzerland.

Introduction: Several recurrently deregulated pathways implicated in the development of chronic lymphocytic leukemia (CLL) have been described over the last decades. Knowledge of the CLL genetic heterogeneity led to the definition of molecular biomarkers informing about prognosis and treatment outcome. Areas covered: English literature published from January 2008 through December 2018 was searched in PubMed, Cochrane Central Register of Controlled Trials, and hematology meeting abstracts to obtain literature on clinical predictive factors for CLL. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1575130DOI Listing
February 2019
7 Reads

Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions.

Expert Rev Hematol 2019 Feb 22;12(2):99-106. Epub 2019 Jan 22.

b Department of Internal Medicine, Division of Blood and Marrow Transplantation , Stanford University School of Medicine , Stanford , CA , USA.

Introduction: Allogeneic hematopoietic cell transplantation (allo-HCT) has seen marked growth among older adults, where chronological age is no longer a barrier to transplant. As allo-HCT expands to older and potentially less fit individuals, prognosticating transplant outcomes in this population remains an ongoing need. Areas covered: This review summarizes pre-transplant assessment tools in optimizing patient selection and predicting transplant outcomes in older adults, including comorbidity indices, psychosocial assessment, geriatric assessment, serum biomarkers, and disease risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1568236DOI Listing
February 2019
1 Read

Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis.

Expert Rev Hematol 2019 Jan 29;12(1):47-60. Epub 2018 Dec 29.

a Stem Cell Transplant Program, University Hospitals Cleveland Medical Center , Case Western Reserve University , Cleveland , OH , USA.

Introduction: Allogeneic hematopoietic cell transplantation is frequently used to treat malignant and non-malignant conditions, and many patients lack a human leukocyte antigen (HLA) matched related or unrelated donor. For those patients, available alternative graft sources include HLA mismatched unrelated donors, cord blood, or haplo-identical donors. These graft sources have unique characteristics and associated outcomes requiring graft-specific variations to conditioning regimens, graft-versus-host disease prophylaxis, and post-transplant care. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1562331DOI Listing
January 2019
16 Reads

Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors.

Expert Rev Hematol 2019 Jan 28;12(1):21-28. Epub 2019 Jan 28.

a Haemophilia Treatment Centre , University Hospital Montpellier , Montpellier , France.

Introduction: Hemophilia A and B are X-linked recessive disorders caused by the deficiency of factor VIII or factor IX, respectively. Bleeding episodes are treated with factor replacement therapy. The most serious complication of this treatment is the development of inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1560259DOI Listing
January 2019
4 Reads

Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.

Expert Rev Hematol 2019 Feb 7;12(2):81-87. Epub 2019 Jan 7.

a Hematology, Department of Cellular Biotechnologies and Hematology , Policlinico Umberto 1, Sapienza University , Rome , Italy.

Introduction: The outcome of acute promyelocytic leukemia (APL) has drastically improved following the identification of the PML-RARA oncogene as a key player in the pathogenesis of APL, and the subsequent introduction of all-trans retinoic acid (ATRA) as a therapeutic agent. Areas covered: Randomized trials have recently demonstrated the efficacy of arsenic trioxide (ATO) in combination with ATRA for the front-line treatment of standard and medium risk APL patients. This chemotherapy-free combination is associated with a decreased cumulative rate of relapse, prolonged overall survival, and reduced early death rate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1562332DOI Listing
February 2019
1 Read

Platelet function assays in diagnosis: an update.

Expert Rev Hematol 2019 Jan 16;12(1):29-46. Epub 2019 Jan 16.

a Department of Medicine, Section of Internal and Cardiovascular Medicine , University of Perugia , Perugia , Italy.

Introduction: Hemorrhagic diseases associated with platelet dysfunction include inherited platelet function disorders (IPFD) and a large number of non-hereditary conditions, defined as acquired platelet function disorders (APFD). Their identification requires a careful clinical evaluation and a rational use of diagnostic laboratory assays. Areas covered: Here we describe the laboratory techniques currently available for the assessment of platelet function, including new and experimental laboratory assays, and their alterations in platelet function disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1562333DOI Listing
January 2019
2 Reads

Brentuximab vedotin in T-cell lymphoma.

Expert Rev Hematol 2019 Jan 18;12(1):5-19. Epub 2018 Dec 18.

a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Australia.

Introduction: Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting agent monomethylauristatin E. The utility of brentuximab vedotin has been explored in a number of diseases, with a recent focus on T-cell lymphoma, particularly systemic anaplastic large-cell lymphoma (sALCL) and cutaneous T-cell lymphoma (CTCL), as well as other peripheral T-cell lymphoma (PTCL) histologies. Areas covered: This review surveys current data on the efficacy of brentuximab vedotin in T-cell lymphoma, as well as embedding it in a therapeutic context by reviewing potential competitor agents in the clinic. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1558399DOI Listing
January 2019
22 Reads

Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA.

Expert Rev Hematol 2019 Jan 12;12(1):71-79. Epub 2018 Dec 12.

c Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited , Cambridge , UK.

Background: Immunomodulator (IMID) and proteasome inhibitor (PI) triplet frontline therapy (FT) in newly diagnosed multiple myeloma (NDMM) trials improve overall survival (OS); reported outcomes in routine practice are lacking. Authors compared outcomes in NDMM patients in the USA by use of triplet vs doublet FTs.

Methods: In this retrospective study of NDMM patients without FT transplant between 1/1/2008 and 6/30/2017, FT was categorized as: PI+IMID-triplet (≥ 3 drugs including PI+IMID), non-PI+IMID-triplet (≥ 3 drugs, not PI+IMID), doublet (≤ 2 drugs). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1555460DOI Listing
January 2019
19 Reads

Measurable residual disease in acute myeloid leukemia using flowcytometry: approaches for harmonization/standardization.

Expert Rev Hematol 2018 Nov 23. Epub 2018 Nov 23.

a Department of Hematology , VU University Medical Center , De Boelelaan 1117, 1081 HV Amsterdam , Netherlands.

Introduction: Measurable Residual Disease (MRD) in acute myeloid leukemia (AML) is a rapidly evolving area with many institutes embarking on it, both in academical and pharmaceutical settings. However, there is a multitude of approaches to design, perform and report flow cytometric MRD. Together with the long-term experience needed, this makes flow cytometric MRD in AML non-standardized and time-consuming. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1549479DOI Listing
November 2018
4 Reads

rFVIIIFC for hemophilia A prophylaxis.

Authors:
Johnny Mahlangu

Expert Rev Hematol 2018 Nov 19. Epub 2018 Nov 19.

a NHLS and the Charlotte Maxeke , Johannesburg academic Hospital, University of the Witwatersrand , Johannesburg , South Africa.

Introduction: rFVIIIFC was the first extended half-life product to complete the phase 3 development program and be registered. It was developed to reduce the high treatment burden imposed by prophylaxis. It is now one of four extended half-life products available for a variety of indications in hemophilia A. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1549478DOI Listing
November 2018
10 Reads

Health-related quality of life in adult primary immune thrombocytopenia.

Expert Rev Hematol 2018 Nov 16:1-11. Epub 2018 Nov 16.

a Depatment of Haematology , Odense University Hospital , Odense , Denmark.

Introduction: Immune thrombocytopenia (ITP) and the associated biologic and psychological effects can lead to reduced health-related quality of life (HRQoL). Areas covered: This review focuses on the impact of ITP itself and its treatment on patients' HRQoL. The findings show that the HRQoL is uniformly reduced amongst ITP patients, both with and without interventions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1548930DOI Listing
November 2018
12 Reads

Current strategies for hemostatic control in acute trauma hemorrhage and trauma-induced coagulopathy.

Expert Rev Hematol 2018 Nov 15:1-9. Epub 2018 Nov 15.

b Department of Traumatology and Orthopaedic Surgery, Cologne-Merheim Medical Centre (CMMC) , Witten/Herdecke University , Cologne , Germany.

Introduction: Despite advances in the treatment of severely injured patients that have resulted in overall improved outcomes, uncontrolled hemorrhage still represents the most common cause of preventable death following major injury. While addressing both endo- and exogenous factors that lead to an acute trauma-induced coagulopathy, massive transfusion plays a key role in managing bleeding trauma patients. However, the best practice for hemostatic control including massive transfusion in these patients is still under debate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1548929DOI Listing
November 2018
3 Reads

Venetoclax for the treatment of multiple myeloma.

Expert Rev Hematol 2018 Nov 14. Epub 2018 Nov 14.

a Division of Hematology , Mayo Clinic , Rochester , MN , USA.

Introduction: Treatment of multiple myeloma in the relapsed setting remains challenging, despite recent impressive advances in the management of these patients. Venetoclax (ABT-199) is a BCL-2 inhibitor recently approved by the US food and drug administration (FDA) for treatment of chronic lymphocytic leukemia but the drug has shown activity in a number of hematological malignancies. Venetoclax has broadened the treatment options for patients with relapsed or refractory multiple myeloma. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1548931DOI Listing
November 2018
22 Reads

Time for patient reported outcomes assessment in routine hematology practice: the case of chronic myeloid leukemia.

Expert Rev Hematol 2019 Jan 14;12(1):1-3. Epub 2018 Nov 14.

a Data Center and Health Outcomes Research Unit , Italian Group for Adult Hematologic Diseases (GIMEMA) , Rome , Italy.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1547189DOI Listing
January 2019
5 Reads

Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.

Expert Rev Hematol 2018 Dec 8;11(12):945-956. Epub 2018 Nov 8.

a Department of Pediatric Hematology and Oncology , IRCCS, Ospedale Pediatrico Bambino Gesù , Rome , Italy.

Introduction: The clinical application of immunotherapy has resulted into a significant improvement in the outcome of children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL). In this setting, the use of bispecific T-cell-engager antibodies (BiTEs), such as blinatumomab, which harness the cytotoxic activity of T cells against CD19-positive lymphoblasts, has emerged as a most promising and impactful strategy. Areas covered: This review discusses the main structural and functional features of BiTEs, as well as the current status of their clinical application in childhood ALL. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1540928DOI Listing
December 2018
6 Reads

Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities.

Expert Rev Hematol 2018 Oct 19. Epub 2018 Oct 19.

c Division of Medical Oncology, Department of Medicine , University of Washington , Seattle , WA.

Introduction: Multiple three drug combination regimens have been approved for the treatment of multiple myeloma in the last few years. Triplets have become the new standard of care for transplant eligible and ineligible patients with newly diagnosed as well as relapsed multiple myeloma. Novel agents have a unique profile of side effects. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1538777DOI Listing
October 2018
35 Reads

Optimal frontline management of mantle cell lymphoma: can we agree?

Expert Rev Hematol 2018 Oct 19:1-4. Epub 2018 Oct 19.

a Division of Medical Oncology & Hematology , Princess Margaret Cancer Centre , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1537778DOI Listing
October 2018
2 Reads

An update on treatment of higher risk myelodysplastic syndromes.

Expert Rev Hematol 2019 Jan 18;12(1):61-70. Epub 2018 Dec 18.

a Service Hématologie Séniors, Hôpital Saint Louis , Université Paris Diderot, Assistance Publique-Hôpitaux de Paris , Paris , France.

Introduction: Myelodysplastic syndromes (MDS) are clonal stem cell disorders mostly affecting the elderly. They are classified into lower and higher risk MDS according to prognostic scoring systems. In higher risk patients, treatments should aim to modify the disease course by avoiding progression to acute myeloid leukemia and, therefore, to improve survival. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1537777DOI Listing
January 2019
9 Reads

Prognostic factors for multiple myeloma in the era of novel therapies.

Expert Rev Hematol 2018 Nov 26;11(11):863-879. Epub 2018 Oct 26.

a Department of Clinical Therapeutics, School of Medicine, "Alexandra" General Hospital , National and Kapodistrian University of Athens , Athens , Greece.

Introduction: Multiple myeloma (MM) is characterized by notable inter-patient and intra-clonal heterogeneity that is gradually decoded over the last decade. Despite the deeper and better understanding of its biology and the development of novel therapeutic strategies that have prolonged overall survival, MM still retains a poor prognosis in patient subgroups with certain high-risk features. Areas covered: This article summarizes currently identified features that stratified patients in high-risk myeloma with impaired prognosis and discusses available therapeutic options that may partially overcome the impact of these adverse factors in patients' outcome. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1537776DOI Listing
November 2018
23 Reads

Novel treatments to tackle myelofibrosis.

Expert Rev Hematol 2018 Nov 26;11(11):889-902. Epub 2018 Oct 26.

a Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , Myeloproliferative Neoplasms Research Program , New York , NY , USA.

Introduction: Despite the dramatic progress made in the treatment of patients with myelofibrosis since the introduction of the JAK1/2 inhibitor ruxolitinib, a therapeutic option that can modify the natural history of the disease and prevent evolution to blast-phase is still lacking. Recent investigational treatments including immunomodulatory drugs and histone deacetylase inhibitors benefit some patients but these effects have proven modest at best. Several novel agents do show promising activity in preclinical studies and early-phase clinical trials. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1536538DOI Listing
November 2018
43 Reads

Andexanet alfa for the treatment of hemorrhage.

Expert Rev Hematol 2018 Nov 17;11(11):847-855. Epub 2018 Oct 17.

b Department of Pathology and Molecular Medicine, Faculty of Health Sciences , McMaster University , Hamilton , Ontario , Canada.

Introduction: While associated life-threatening and fatal bleeding events are less frequent with the direct factor Xa inhibitors compared to vitamin K antagonists, significant concern surrounding management of major bleeds and urgent periprocedural interruption of these agents exists among clinicians. Andexanet alfa is a recombinant human factor Xa decoy protein developed in response to this clinical gap in the care of patients receiving anticoagulation with factor Xa inhibitors. Areas covered: This paper reviews results from preclinical and healthy-volunteer studies demonstrating the ability of andexanet to rapidly and reliably normalize coagulation indices in patients treated with both direct and indirect factor Xa inhibitors. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1532287DOI Listing
November 2018
5 Reads

The importance of inhibitor eradication in clinically complicated hemophilia A patients.

Expert Rev Hematol 2018 Nov 4;11(11):857-862. Epub 2018 Oct 4.

f Hemophilia Center Rhein-Main - HZRM , Frankfurt - Mörfelden , Germany.

Introduction: Inhibitors against factor VIII (FVIII), which develop in around 20-30% of patients with severe hemophilia A, represent a significant complication of on-demand or prophylactic FVIII therapy. Currently, the main treatment option for inhibitor patients is eradication using immune tolerance induction (ITI) therapy. Areas covered: This article reviews inhibitor eradication in clinically complicated hemophilia A patients. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1521718DOI Listing
November 2018
11 Reads

Management of multiple myeloma bone disease: impact of treatment on renal function.

Expert Rev Hematol 2018 Nov 20;11(11):881-888. Epub 2018 Oct 20.

a Department of Clinical Therapeutics , National and Kapodistrian University of Athens School of Medicine, Alexandra General Hospital , Athens , Greece.

Introduction: Bone disease (BD) is one of the most common features of multiple myeloma. Seventy to eighty percent of patients at diagnosis present with lytic lesions which may lead to skeletal-related events. Areas covered: The aim of this review is to present the possible adverse profile of bisphosphonates (BPs) on renal function, the underlying mechanisms by which BPs may affect renal function and the novel therapeutic approaches on myeloma bone disease management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1531702DOI Listing
November 2018
5 Reads